We have previously demonstrated that the multikinase inhibitors (MKI) Pazopanib and Sorafenib targeting the PDGFR among other tyrosine kinase receptors and the direct PI3K‐inhibitor Pictilisib (GDC‐0941) exhibit potent anti‐neoplastic capacities in orthotopic xenograft models of medulloblastoma including anti‐migratory effects in vitro.23, 24. This evidence concerns the gene NTRK1 and medulloblastoma.